{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T19:38:14Z","timestamp":1781811494060,"version":"3.54.5"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,7,11]],"date-time":"2012-07-11T00:00:00Z","timestamp":1341964800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Med. Toxicol."],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s13181-012-0248-9","type":"journal-article","created":{"date-parts":[[2012,7,10]],"date-time":"2012-07-10T19:14:42Z","timestamp":1341947682000},"page":"314-321","source":"Crossref","is-referenced-by-count":50,"title":["4-Aminopyridine Toxicity: a Case Report and Review of the Literature"],"prefix":"10.1007","volume":"8","author":[{"given":"Andrew M.","family":"King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan B.","family":"Menke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth D.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony F.","family":"Pizon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,7,11]]},"reference":[{"key":"248_CR1","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/0041-008X(73)90291-3","volume":"26","author":"EW Schafer Jr","year":"1978","unstructured":"Schafer EW Jr, Brunton RB, Cunningham DJ (1978) A summary of the acute toxicity of 4-aminopyridine to birds and mammals. Toxicol App Pharmacol 26:532\u2013538","journal-title":"Toxicol App Pharmacol"},{"issue":"6","key":"248_CR2","first-page":"350","volume":"43","author":"K Bischoff","year":"2001","unstructured":"Bischoff K, Morgan S, Chelsvig J, Spencer D (2001) 4-Aminopyridine poisoning of crows in the Chicago area. Vet Hum Toxicol 43(6):350\u2013352","journal-title":"Vet Hum Toxicol"},{"issue":"4","key":"248_CR3","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/j.1471-4159.1990.tb01963.x","volume":"54","author":"RL Buyukuysal","year":"1990","unstructured":"Buyukuysal RL, Wurtman RJ (1990) 4-Aminopyridine increases acetylcholine release without diminishing membrane phosphatidylcholine. J Neurochem 54(4):1302\u20131309","journal-title":"J Neurochem"},{"issue":"1","key":"248_CR4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0014-2999(88)90343-3","volume":"145","author":"G Damsma","year":"1988","unstructured":"Damsma G, Biessels PT, Westerink BH et al (1988) Differential effects of 4-aminopyridine and 2,4-diaminopyridine on the in vivo release of acetylcholine and dopamine in freely moving rats measured by intrastriatal dialysis. Eur J Pharmacol 145(1):15\u201320","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"248_CR5","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/0028-3908(94)90141-4","volume":"33","author":"S Jin","year":"1994","unstructured":"Jin S, Fredholm BB (1994) Role of NMDA, AMPA and kainate receptors in mediating glutamate- and 4-AP-induced dopamine and acetylcholine release from rat striatal slices. Neuropharmacology 33(9):1039\u20131048","journal-title":"Neuropharmacology"},{"key":"248_CR6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF00586945","volume":"379","author":"H Folgering","year":"1979","unstructured":"Folgering H, Rutten J, Agoston S (1979) Stimulation of phrenic nerve activity by an acetylcholine releasing drug: 4-aminopyridine. Pfluger Arch 379:181\u2013185","journal-title":"Pfluger Arch"},{"key":"248_CR7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF01252021","volume":"41","author":"ES Vizi","year":"1977","unstructured":"Vizi ES, van Dijk J, Foldes FF (1977) The effect of 4-aminopyridine on acetylcholine release. J Neural Transm 41:265\u2013274","journal-title":"J Neural Transm"},{"issue":"3","key":"248_CR8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3109\/15563659509017992","volume":"33","author":"CE Boerma","year":"1995","unstructured":"Boerma CE, Rommes JH, van Leeuwen RB, Bakker J (1995) Cardiac arrest following an iatrogenic 3,4-diaminopyridine intoxication in a patient with Lambert\u2013Eaton myasthenic syndrome. J Toxicol Clin Toxicol 33(3):249\u2013251","journal-title":"J Toxicol Clin Toxicol"},{"key":"248_CR9","first-page":"CD003279","volume":"2","author":"P Maddison","year":"2005","unstructured":"Maddison P, Newsom-Davis J (2005) Treatment for Lambert Eaton myasthenic syndrome. Cochrane Database Syst Rev 2:CD003279","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"248_CR10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/jnnp.42.2.171","volume":"42","author":"H Lundh","year":"1979","unstructured":"Lundh H, Nilsson O, Ros\u00e9n I (1979) Effects of 4-aminopyridine in myasthenia gravis. J Neurol Neurosurg Psychiatry 42(2):171\u2013175","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"248_CR11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/0041-0101(95)00167-0","volume":"34","author":"FC Chang","year":"1996","unstructured":"Chang FC, Bauer RM, Benton BJ et al (1996) 4-Aminopyridine antagonizes saxitoxin-and tetrodotoxin-induced cardiorespiratory depression. Toxicon 34(6):671\u2013690","journal-title":"Toxicon"},{"key":"248_CR12","first-page":"473","volume":"48","author":"AP Ball","year":"1979","unstructured":"Ball AP, Hopkinson RB, Farrell ID et al (1979) Human botulism caused by Clostridium botulinum type E: The Birmingham outbreak. Q J Med 48:473\u2013491","journal-title":"Q J Med"},{"issue":"3","key":"248_CR13","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/IAI.52.3.858-862.1986","volume":"52","author":"LL Simpson","year":"1986","unstructured":"Simpson LL (1986) A preclinical evaluation of aminopyridines as putative therapeutic agents in the treatment of botulism. Infect Immun 52(3):858\u2013862","journal-title":"Infect Immun"},{"key":"248_CR14","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/283570a0","volume":"283","author":"RM Sherratt","year":"1980","unstructured":"Sherratt RM, Bostock H, Sears TA (1980) Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature 283:570\u2013572","journal-title":"Nature"},{"issue":"1","key":"248_CR15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/brain\/123.1.171","volume":"123","author":"KJ Smith","year":"2000","unstructured":"Smith KJ, Felts PA, John GR (2000) Effects of 4- aminopyridine on demyelinated axons, synapses and muscle tension. Brain 123(1):171\u2013184","journal-title":"Brain"},{"key":"248_CR16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1089\/neu.1991.8.103","volume":"8","author":"AR Blight","year":"1991","unstructured":"Blight AR, Toombs JP, Bauer MS, Widmer WR (1991) The effects of 4-aminopyridine on neurological deficits in chronic cases of traumatic spinal cord injury in dogs: a phase I clinical trial. J Neurotrauma 8:103\u2013119","journal-title":"J Neurotrauma"},{"key":"248_CR17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0022-510X(87)90014-1","volume":"82","author":"AR Blight","year":"1987","unstructured":"Blight AR, Gruner JA (1987) Augmentation by 4- aminopyridine of vestibulospinal free fall responses in chronic spinal-injured cats. J Neurol Sci 82:145\u2013159","journal-title":"J Neurol Sci"},{"issue":"7","key":"248_CR18","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1592\/phco.23.7.823.32731","volume":"23","author":"I Grijalva","year":"2003","unstructured":"Grijalva I, Gu\u00edzar-Sahag\u00fan G, Casta\u00f1eda-Hern\u00e1ndez G et al (2003) Efficacy and safety of 4-aminopyridine in patients with long-term spinal cord injury: a randomized, double-blind, placebo-controlled trial. Pharmacotherapy 23(7):823\u2013834","journal-title":"Pharmacotherapy"},{"issue":"6","key":"248_CR19","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1592\/phco.19.9.713.31540","volume":"19","author":"JL Segal","year":"1999","unstructured":"Segal JL, Pathak MS, Hernandez JP et al (1999) Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: long-term, controlled trial. Pharmacotherapy 19(6):713\u2013723","journal-title":"Pharmacotherapy"},{"key":"248_CR20","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/sj.sc.3101653","volume":"42","author":"D DeForge","year":"2004","unstructured":"DeForge D, Nymark J, Lemaire E et al (2004) Effect of 4- aminopyridine on gait in ambulatory spinal cord injuries: a double-blind, placebo-controlled, crossover trial. Spinal Cord 42:674\u2013685","journal-title":"Spinal Cord"},{"issue":"1","key":"248_CR21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/sj.sc.3100931","volume":"38","author":"WH Donovan","year":"2000","unstructured":"Donovan WH, Halter JA, Graves DE et al (2000) Intravenous infusion of 4-AP in chronic spinal cord injured subjects. Spinal Cord 38(1):7\u201315","journal-title":"Spinal Cord"},{"issue":"8","key":"248_CR22","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s004150170111","volume":"248","author":"MA Bruggen van der","year":"2001","unstructured":"van der Bruggen MA, Huisman HB, Beckerman H et al (2001) Randomized trial of 4-aminopyridine in patients with chronic incomplete spinal cord injury. J Neurol 248(8):665\u2013671","journal-title":"J Neurol"},{"issue":"5","key":"248_CR23","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1089\/neu.2011.2052","volume":"29","author":"A Domingo","year":"2012","unstructured":"Domingo A, Al-Yahya AA, Asiri Y, Eng JJ et al (2012) A systematic review of the effects of pharmacological agents on walking function in people with spinal cord injury. J Neurotrauma 29(5):865\u2013879","journal-title":"J Neurotrauma"},{"issue":"7","key":"248_CR24","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1185\/03007995.2011.583229","volume":"27","author":"J Dunn","year":"2011","unstructured":"Dunn J, Blight A (2011) Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Curr Med Res Opin 27(7):1415\u20131423","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"248_CR25","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/1352458506069538","volume":"13","author":"AD Goodman","year":"2007","unstructured":"Goodman AD, Cohen JA, Cross A et al (2007) Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler 13(3):357\u2013368","journal-title":"Mult Scler"},{"key":"248_CR26","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/clpt.1982.82","volume":"31","author":"DRA Uges","year":"1982","unstructured":"Uges DRA, Sohn YJ, Greijdanus B (1982) 4-Aminopyridine kinetics. Clin Pharmacol Ther 31:587\u2013593","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"248_CR27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0003-9993(03)00651-8","volume":"85","author":"KC Hayes","year":"2004","unstructured":"Hayes KC, Potter PJ, Hsieh JT et al (2004) Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury. Arch Phys Med Rehabil 85(1):29\u201334","journal-title":"Arch Phys Med Rehabil"},{"issue":"3","key":"248_CR28","first-page":"425","volume":"55","author":"J Magdalan","year":"2003","unstructured":"Magdalan J (2003) New treatment methods in verapamil poisoning: experimental studies. Pol J Pharmacol 55(3):425\u2013432","journal-title":"Pol J Pharmacol"},{"issue":"5","key":"248_CR29","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1172\/JCI111331","volume":"73","author":"S Agoston","year":"1984","unstructured":"Agoston S, Maestrone E, van Hezik EJ et al (1984) Effective treatment of verapamil intoxication with 4-aminopyridine in the cat. J Clin Invest 73(5):1291\u20131296","journal-title":"J Clin Invest"},{"issue":"4","key":"248_CR30","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3109\/15563659809028025","volume":"36","author":"Y Tuncok","year":"1998","unstructured":"Tuncok Y, Apaydin S, Gelal A et al (1998) The effects of 4-aminopyridine and Bay K 8644 on verapamil-induced cardiovascular toxicity in anesthetized rats. J Toxicol Clin Toxicol 36(4):301\u2013307","journal-title":"J Toxicol Clin Toxicol"},{"issue":"6","key":"248_CR31","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1172\/JCI112505","volume":"77","author":"R Gay","year":"1986","unstructured":"Gay R, Algeo S, Lee RJ et al (1986) Treatment of verapamil toxicity in intact dogs. J Clin Invest 77(6):1805\u20131811","journal-title":"J Clin Invest"},{"issue":"2","key":"248_CR32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s13181-010-0073-y","volume":"6","author":"A Graudins","year":"2010","unstructured":"Graudins A, Wong KK (2010) Comparative hemodynamic effects of levosimendan alone and in conjunction with 4-aminopyridine or calcium chloride in a rodent model of severe verapamil poisoning. J Med Toxicol 6(2):85\u201393","journal-title":"J Med Toxicol"},{"issue":"4","key":"248_CR33","first-page":"271","volume":"60","author":"J Magdalan","year":"2003","unstructured":"Magdalan J, Kochman K, Anto\u0144czyk A et al (2003) Successful treatment by 4-aminopyridine of three cases of severe verapamil poisoning. Przegl Lek 60(4):271\u2013273","journal-title":"Przegl Lek"},{"issue":"4","key":"248_CR34","first-page":"268","volume":"60","author":"J Magdalan","year":"2003","unstructured":"Magdalan J, Kochman K, Smolarek M et al (2003) Severe felodipine and theophylline poisoning successfully treated by 4-aminopyridine: a case report. Przegl Lek 60(4):268\u2013270","journal-title":"Przegl Lek"},{"issue":"6","key":"248_CR35","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1365-2710.2007.00861.x","volume":"32","author":"B Wilffert","year":"2007","unstructured":"Wilffert B, Boskma RJ, van der Voort PH et al (2007) 4-Aminopyridine (fampridine) effectively treats amlodipine poisoning: a case report. J Clin Pharm Ther 32(6):655\u2013657","journal-title":"J Clin Pharm Ther"},{"issue":"4\u20135","key":"248_CR36","first-page":"293","volume":"64","author":"M Fiszer","year":"2007","unstructured":"Fiszer M, Ko\u0142aci\u0144ski Z, Rechci\u0144ski T (2007) The application of 4-aminopyridine in calcium channel inhibitors acute poisoning. Przegl Lek 64(4\u20135):293\u2013297","journal-title":"Przegl Lek"},{"issue":"9","key":"248_CR37","first-page":"1655","volume":"42","author":"L Klein","year":"1981","unstructured":"Klein L, Hopkins J (1981) Behavioral and cardiorespiratory responses to 4-aminopyridine in healthy awake horses. Am J Vet Res 42(9):1655\u20131657","journal-title":"Am J Vet Res"},{"issue":"2","key":"248_CR38","first-page":"329","volume":"39","author":"AC Ray","year":"1978","unstructured":"Ray AC, Dwyer JN, Fambro GW, Reagor JC (1978) Clinical signs and chemical confirmation of aminopyridine poisoning in horses. Am J Vet Res 39(2):329\u2013331","journal-title":"Am J Vet Res"},{"key":"248_CR39","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3109\/15563658008989978","volume":"16","author":"DA Spyker","year":"1980","unstructured":"Spyker DA, Lynch C, Shabanowitz J, Sinn JA (1980) Poisoning with 4-aminopyridine: report of three cases. Clin Toxicol 16:487\u2013497","journal-title":"Clin Toxicol"},{"key":"248_CR40","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1212\/01.wnl.0000326213.89576.0e","volume":"71","author":"AD Goodman","year":"2008","unstructured":"Goodman AD, Brown TR, Cohen JA et al (2008) Dose-comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 71:1134\u20131141","journal-title":"Neurology"},{"key":"248_CR41","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3109\/15563659409011063","volume":"32","author":"CM Stork","year":"1994","unstructured":"Stork CM, Hoffman RS (1994) Characterization of 4-aminopyridine in overdose. J Toxicol Clin Toxicol 32:583\u2013587","journal-title":"J Toxicol Clin Toxicol"},{"key":"248_CR42","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S0196-0644(96)70277-9","volume":"3","author":"TA Pickett","year":"1996","unstructured":"Pickett TA, Enns R (1996) Atypical presentation of 4-aminopyridine overdose. Ann Emerg Med 3:382\u2013385","journal-title":"Ann Emerg Med"},{"issue":"51","key":"248_CR43","first-page":"2667","volume":"139","author":"JW Smeets","year":"1995","unstructured":"Smeets JW, Kunst MW (1995) Severe poisoning by 4-aminopyridine in a body builder. Ned Tijdschr Geneeskd 139(51):2667\u20132669","journal-title":"Ned Tijdschr Geneeskd"},{"key":"248_CR44","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1542\/peds.111.1.e82","volume":"111","author":"L Velez","year":"2003","unstructured":"Velez L, Shirazi F, Goto C et al (2003) Opisthotonic posturing with neuromuscular irritability attributable to 4-aminopyridine ingestion in a healthy pediatric patient. Pediatrics 111:e82\u2013e84","journal-title":"Pediatrics"},{"key":"248_CR45","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jemermed.2005.04.020","volume":"30","author":"NC Johnson","year":"2006","unstructured":"Johnson NC, Morgan MW (2006) An unusual case of 4-aminopyridine toxicity. J Emerg Med 30:175\u2013177","journal-title":"J Emerg Med"},{"key":"248_CR46","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1212\/01.wnl.0000339380.23073.58","volume":"71","author":"JM Burton","year":"2008","unstructured":"Burton JM, Bell CM, Walker SE et al (2008) 4-Aminopyridine toxicity with unintentional overdosage in four patients with multiple sclerosis. Neurology 71:1833\u20131834","journal-title":"Neurology"},{"key":"248_CR47","first-page":"40","volume":"109","author":"H Cauwer De","year":"2009","unstructured":"De Cauwer H, De Wolf P, Couvreur F et al (2009) An unusual case of 4-aminopyridine toxicity in a multiple sclerosis patient: epileptic disorder or toxic encephalopathy? Acta Neurol Belg 109:40\u201341","journal-title":"Acta Neurol Belg"},{"issue":"12","key":"248_CR48","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1212\/01.wnl.0000345063.17185.13","volume":"72","author":"A Badruddin","year":"2009","unstructured":"Badruddin A, Menon RS, Reder AT (2009) 4-Aminopyridine toxicity mimics autoimmune-mediated limbic encephalitis. Neurology 72(12):1100\u20131101","journal-title":"Neurology"},{"issue":"1","key":"248_CR49","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jemermed.2009.04.037","volume":"41","author":"E Schwam","year":"2009","unstructured":"Schwam E (2009) Severe accidental overdose of 4-aminopyridine due to a compounding pharmacy error. J Emerg Med 41(1):51\u201354","journal-title":"J Emerg Med"},{"issue":"4","key":"248_CR50","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/0091270003251388","volume":"43","author":"KC Hayes","year":"2003","unstructured":"Hayes KC, Katz MA, Devane JG et al (2003) Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury. J Clin Pharmacol 43(4):379\u2013385","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"248_CR51","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1016\/j.clinthera.2009.10.008","volume":"31","author":"T Vollmer","year":"2009","unstructured":"Vollmer T, Henney HR (2009) Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a phase I\u2013II, open-label trial. Clin Ther 31(10):2206\u20132214","journal-title":"Clin Ther"},{"issue":"3","key":"248_CR52","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/archneur.1994.00540150090022","volume":"51","author":"CH Polman","year":"1994","unstructured":"Polman CH, Bertelsmann FW, van Loenen AC, Koetsier JC (1994) 4-Aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Arch Neurol 51(3):292\u2013296","journal-title":"Arch Neurol"},{"issue":"2","key":"248_CR53","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/ana.410320203","volume":"32","author":"HA Diemen van","year":"1992","unstructured":"van Diemen HA, Polman CH, van Dongen TM et al (1992) The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol 32(2):123\u2013130","journal-title":"Ann Neurol"},{"issue":"10","key":"248_CR54","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1345\/aph.1L028","volume":"42","author":"AR Korenke","year":"2008","unstructured":"Korenke AR, Rivey MP, Allington DR (2008) Sustained-release fampridine for symptomatic treatment of multiple sclerosis. Ann Pharmacother 42(10):1458\u20131465","journal-title":"Ann Pharmacother"},{"key":"248_CR55","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(09)60442-6","volume":"373","author":"AD Goodman","year":"2009","unstructured":"Goodman AD, Brown TR, Krupp L et al (2009) Sustained release of oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 373:732\u2013738","journal-title":"Lancet"},{"key":"248_CR56","unstructured":"Acorda therapeutics: Data on file. Integrated Summary of Safety. Fampridine-SR in patients with Multiple Sclerosis. NDA 22\u2013250, 2009"},{"key":"248_CR57","first-page":"CD001330","volume":"2","author":"A Solari","year":"2003","unstructured":"Solari A, Uitdehaag B, Guliani G et al (2003) Aminopyridines for symptomatic treatment in multiple sclerosis. Cochrane Database Syst Rev 2:CD001330","journal-title":"Cochrane Database Syst Rev"},{"key":"248_CR58","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2165\/11310900-000000000-00000","volume":"23","author":"BJ Kelley","year":"2009","unstructured":"Kelley BJ, Rodriguez M (2009) Seizures in patients with multiple sclerosis: epidemiology, pathophysiology and management. CNS Drugs 23:805\u2013815","journal-title":"CNS Drugs"},{"issue":"6","key":"248_CR59","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.44.6.1054","volume":"44","author":"CT Bever Jr","year":"1994","unstructured":"Bever CT Jr, Young D, Anderson PA et al (1994) The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 44(6):1054\u20131059","journal-title":"Neurology"},{"issue":"3","key":"248_CR60","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00002826-199306000-00002","volume":"16","author":"HA Diemen Van","year":"1993","unstructured":"Van Diemen HA, Polman CH, Koetsier JC et al (1993) 4-Aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety. Clin Neuropharmacol 16(3):195\u2013204","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"248_CR61","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1753-5174.2009.00021.x","volume":"2","author":"M Renganathan","year":"2009","unstructured":"Renganathan M, Sidach S, Blight AR (2009) Effects of 4-Aminopyridine on Cloned hERG Channels Expressed in Mammalian Cells. Arch Drug Inf 2(3):51\u201357","journal-title":"Arch Drug Inf"},{"key":"248_CR62","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1517\/13543780903443096","volume":"18","author":"B March","year":"2009","unstructured":"March B, Cardi T (2009) Assessment of the cardiac safety of fampridine-SR sustained-release tablets in a thorough QT\/QTc evaluation at therapeutic and supratherapeutic doses in healthy individuals. Expert Opin Investig Drugs 18:1807\u20131815","journal-title":"Expert Opin Investig Drugs"},{"key":"248_CR63","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1592\/phco.23.2.133.32089","volume":"23","author":"WC Isoda","year":"2003","unstructured":"Isoda WC, Segal JL (2003) Effects of 4-aminopyridine on cardiac repolarization, PR interval, and heart rate in patients with spinal cord injury. Pharmacotherapy 23:133\u2013136","journal-title":"Pharmacotherapy"},{"key":"248_CR64","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0920-1211(92)90016-M","volume":"11","author":"S Yamaguchi","year":"1992","unstructured":"Yamaguchi S, Rogawski MA (1992) Effects of anticonvulsant drugs on 4-aminopyridine-induced seizures in mice. Epilepsy Res 11:9\u201316","journal-title":"Epilepsy Res"},{"issue":"8","key":"248_CR65","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2165\/11207350-000000000-00000","volume":"25","author":"LJ Scott","year":"2011","unstructured":"Scott LJ (2011) Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis. CNS Drugs 25(8):673\u2013698","journal-title":"CNS Drugs"}],"container-title":["Journal of Medical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-012-0248-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13181-012-0248-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-012-0248-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T14:46:53Z","timestamp":1594392413000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13181-012-0248-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,11]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["248"],"URL":"https:\/\/doi.org\/10.1007\/s13181-012-0248-9","relation":{},"ISSN":["1556-9039","1937-6995"],"issn-type":[{"value":"1556-9039","type":"print"},{"value":"1937-6995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,11]]}}}